
Kestra Medical Technologies rose 11.4% from $25.10 to $27.97, ahead of the S&P 500's +11.2%. Its worst day was Mar 12 (−14.1%), and its low came Apr 10 at $17.87.
Nov 17, 2025 – Nov 16, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-0.64 missed the $-0.57 estimate on $22.6M revenue (est. $21.0M); FY revenue guidance of $91.0M against the $88.0M consensus.
+5.1% · S&P 500 −1.1%
Story events cover the past 12 months · Times ET
EPS of $-0.61 missed the $-0.60 estimate on $24.6M revenue (est. $22.9M); FY revenue guidance of $93.0M against the $91.0M consensus.
−7.4% · S&P 500 −1.4%
Kestra Medical Technologies closed at its lowest level of the year, 28.8% below where the year started.
−7.2% · S&P 500 −0.1%
Kestra Medical Technologies shares fell 10.2%, while the S&P 500 fell 1.2%.
−10.2% · S&P 500 −1.2%
Kestra Medical Technologies shares rose 17.1%, while the S&P 500 fell 0.7%.
+17.1%, the year's best day · S&P 500 −0.7%
EPS of $-0.67 missed the $-0.58 estimate on $28.6M revenue (est. $26.5M); FY revenue guidance of $137.0M against the $133.0M consensus.
+1.8% · S&P 500 +0.4%
EPS of $-0.75 missed the $-0.62 estimate on $31.0M revenue (est. $29.0M); FY revenue guidance of $141.0M against the $137.1M consensus.
+4.7% · S&P 500 −0.5%
Kestra Medical Technologies shares rose 12.6%, while the S&P 500 rose 0.3%.
+12.6% · S&P 500 +0.3%
Kestra Medical Technologies closed at its highest level of the year, 26.0% above where the year started.
+7.0% · S&P 500 +1.3%
Where it ended: a close of $27.97 on Nov 16, 2026. Up next: Q2 2027 earnings on Dec 10, 2026 (EPS est. $-0.61, revenue est. $32.1M).
Nothing in the past 12 months.
All KMTS dividend historyReplay the year: the line draws itself and stops at each of the 9 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for KMTS and SPY from Benzinga historical bars. Not investment advice.